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Representing one of the world’s leading causes of death, 
cancer accounted for 22% of the recorded fatalities in the 
United States in 2015 (1). Cancer arises from a complex 
interplay of genetic and epigenetic alterations that can 
result in dysregulation of signalling networks (2). One 
such network is the Hippo pathway, which has been 
demonstrated to act, among other processes, in the control 
of proliferation and organ size (3). The mammalian Hippo 
pathway core cassette consists of upstream kinases (MST1 
and MST2) and downstream kinases (LATS1 and LATS2). 
The interaction between the upstream and downstream 
kinases is assisted by the scaffold protein SAV. Active Hippo 
signalling leads to the MST-dependent phosphorylation 
of LATS and its coactivator MOB1. Key effectors of the 
Hippo signalling pathway are the paralogues YAP and TAZ, 
both of which can act as potent oncogenes (4). TAZ has 
been shown to promote anchorage-independent growth 
and tumorigenesis in breast cancer cells (5) while enhancing 
proliferation and transformation in lung cancer cells (6). 
The activity of both YAP and TAZ is negatively regulated 
by the phosphorylated Hippo core cassette (7), highlighting 
the role of the Hippo pathway in tumor suppression.
In recent years, it has become obvious that a complex 
crosstalk exists between the cancer microenvironment and 
the immune system (8). Interactions between cancer and 
immune cells reduce immune responses, lead to enhanced 
tumor growth, induce immune cell apoptosis, and ultimately 
promote cancer immune evasion. The transmembrane 
protein programmed death-ligand 1 (PD-L1) and its 
receptor PD-1 have emerged as key elements in tumor-
induced immunosuppression (9). PD-L1 is frequently found 
on the plasma membrane of cancer cells and can bind to 
T-cell expressed PD-1, resulting in T cell apoptosis. This 
interaction allows tumor cells to escape the immune system.
Previous studies suggest that the Hippo pathway is 
involved in the cancer-induced immune response (10,11). 
However, the transcriptional targets of YAP and TAZ in 
the context of immunoevasion are poorly understood. 
A genetic screen by Janse van Rensburg et al. identifies 
a range of candidate immune targets of YAP/TAZ (12). 
While 35 genes were shown to be regulated by TAZ 
alone, 12 genes were regulated by YAP only; 24 genes 
were regulated by both YAP and TAZ. Given its role in 
cancer immune evasion, the authors chose to further study 
PD-L1. Overexpression of YAP or TAZ lead to elevated 
protein levels of PD-L1, as did depletion of components 
of the Hippo core cassette. Overexpression of LATS2 had 
the opposite effect. PD-L1 protein expression was also 
induced by overexpression of TAZ in lung cancer cells. 
The study further showed that TAZ and PD-L1 are co-
expressed in several breast and lung cancers in the TCGA 
dataset. In some cancer cell lines, depletion of TAZ lead to 
a decrease in PD-L1 protein expression, which was rescued 
by restoring TAZ expression. TAZ-dependent regulation of 
PD-L1 required transcriptional activators from the TEAD 
family. Expression of a mutant form of TAZ incapable of 
TEAD binding or knockdown of TEAD1/3/4 resulted in 
a reduced expression of PD-L1. Co-expression of TEAD-
binding mutant TAZ and TEAD1–4 produced an increase 
in PD-L1 promoter activity. A deletion scan of the PD-L1 
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promoter identified a putative TEAD-response element. 
Importantly, TAZ overexpression in lung and breast 
cancer cell lines impaired Jurkat T cell function via PD-
L1-mediated induction of apoptosis. Blocking of PD-L1 
suppressed apoptosis of T cells that had been elicited by 
TAZ overexpression in lung cancer cells. T cells showed 
diminished IL-2 production when co-cultured with TAZ-
overexpressing lung cancer cells. This phenotype was 
rescued by a PD-L1-specific antibody. 
Intriguingly, PD-L1 regulation by TAZ is not conserved 
between mice and humans. PD-L1 expression did not 
respond to TAZ in mouse cell lines, and the authors did 
not identify a TEAD response element in the mouse PD-
L1 promoter. This highlights that care needs to be taken 
when using model organisms, at least in the context of 
immunoresponse studies of cancer.
The Hippo pathway and its effector TAZ play a crucial 
role in cancer immune evasion (9). The report by Janse van 
Rensburg et al. (12) has provided important novel insights 
into the molecular mechanisms which allow tumor cells 
to escape immune surveillance, thereby promoting cancer 
progression. The data presented indicates that through its 
effector TAZ, the Hippo pathway integrates input from a 
number of upstream signalling pathways. Unravelling the 
particular cellular (and individual) contexts in which this 
is relevant to cancer will establish criteria that will help 
design patient-based treatment approaches. A profound 
understanding of the interplay between cancer and the 
immune system is paramount to the development and 
improvement of cancer therapies, especially in the context 
of immunotherapy (8). Janse van Rensburg et al. (12) 
made a significant contribution to the current knowledge 
about species-specific regulation of immune-related genes, 
underlining the importance to choose appropriate model 
systems when studying tumor immunology. More extensive 
research on immune targets that are differently regulated 
between species will be needed to ensure the success of 
further studies in this field.
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